Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

s marketing partner, Paladin Labs Inc., launched once-daily tramadol in Canada under the brand name Tridural(TM). The Company also completed licensing and distribution agreements for once-daily tramadol for South Korea with WhanIn Pharmaceutical Co., Ltd., for Greece with Lavipharm S.A. and for Israel with Dexcel Pharma Technologies Ltd. Labopharm expects its product to be launched in the South Korean and Greek markets in 2008. Labopharm's formulation is currently under regulatory review in Israel and the Company expects a response from the Israeli regulatory authority by mid-2008.

To date, Labopharm has secured marketing partners for its once-daily tramadol in more than 50 countries worldwide and regulatory approval in 25 countries. The Company's partners will continue to launch its product in additional markets, globally, throughout 2008.

In the U.S., Labopharm continues to vigorously pursue regulatory approval of its once-daily tramadol, appealing the U.S. Food and Drug Administration's (FDA) decision in its Approvable Letter through initiation of the Agency's Formal Dispute Resolution process. The Company believes that it has met the statutory standards for approval of its formulation and that appealing the FDA's decision through this process represents its best opportunity to expeditiously resolve this matter.

---------------------------------

(1) Labopharm's target market consists of the market for

immediate-release, twice-daily, once-daily and drop formulations of

tramadol.

(2) Includes France, Germany, the United Kingdom, Spain and Italy.

Once-Daily Trazodone Development Program

Labopharm has completed patient enrolment in its North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone, ahead of schedule. More than 400 patients are enrolled in the study.

"Our once-daily formulation represents the opportunity to address significant unmet needs in t
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)... Upstate HomeCare, a home medical services p...tion, respiratory and DME services, is expanding. ...ne specializes in home infusion therapy and one in...omeCare. , Clinton, NY (P...medical services provider specializing in infusion...
(Date:7/2/2009)... State Leaders to Support Principles to Govern Hea...ly 2 Nearly nine out of...mpanies have too much influence over how doctors c...voters support the concept of a "Health Insurer Co...ing principles for health insurance companies with...
(Date:7/2/2009)... Pro-life forces won an...Court ruled to uphold a state law regulating that ...es in administering RU-486 (also known as the "abo...en using the drug. , , The ruling came in Rog... Parenthood to a 2004 law requiring that those adm...
(Date:7/2/2009)...uly 2 A new analysis of...00 women between the ages of 0 to 84 from 2000 to ...ates issued by the Ministry of Health, with the sh...st group studied (ages 25 to 44). , , The new r...at track major breast surgeries rather than offici...
Breaking Medicine News(10 mins):Health News:Upstate HomeCare Expands, Adds Pharmacies 2Health News:Upstate HomeCare Expands, Adds Pharmacies 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 3
...rtmouth Medical School and Dartmouth College, have... changing muscle metabolism and performance. // Th...ould assist in the management of muscle diseases. ... enzyme called AMP-activated protein kinase (or AM...
...t activates the immune systems in colorectal cance... clinical trial of 67 patients, researchers at the... vaccines were injected pre and post surgery of th...mmune cell production in nearly 70 percent of pati...
...t requires extensive medical intervention, a small...another grave condition known as Nephrogenic Syste...NSF/NFD). // First recognized as a disease in 1997...tightening of the skin, resulting in pain, muscle ...
...ept along the continent has lead to the shut down ...al, one of Toronto's largest cataract centres last...00 eye operations a year, decided to cancel all ca...9, when more and more patients came down with the ...
Other Medicine News:Health News:Dartmouth researchers zero-in on a gene that heightens muscle performance 2Health News:A novel vaccine proves a shot in the arm for colorectal cancer patients 2Health News:Dermatologists Provide Unique Evidence of Possible Cause of Rare Skin Condition 2Health News:Eye Surgeries Remain Cancelled Due To TASS Outbreak In Toronto 2
(Date:7/3/2009)..., TURKU, Finland, July 3 Bi...nt company with its headquarters in Turku, Finland...linical trial of ProtoCure(TM),emulsion cream, th...is,double-blind, placebo-controlled study, conduc... moderate atopic dermatitis who applied the ProtoC...
(Date:7/2/2009)..., TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNew...esident & CEO: Haruo Naito, "Eisai") and Eisai...liff Lake, NJ, Chairman and CEO Hajime Shimizu) ar... programs for the company,s major product Aricept(...ntribute to patients with Alzheimer,s disease. As ...
(Date:6/30/2009)..., GLENDALE, Calif., June 30 If ... away you may want to think again. While there is...lic actually keeps mosquitoes away, spraying garli...ay. , , Spraying garlic extract on grassy lawn... a product from Garlic Research Labs, Inc. is bein...
(Date:6/30/2009)..., FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -... that it has submitted a supplemental New Drug App...ration (FDA) requesting approval of NUVIGIL(R) (ar...proved wakefulness in patients with excessive slee...from eastbound travel. Jet lag disorder is an acu...
Breaking Medicine Technology:BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 2Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value 2Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value 3Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc. 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 3Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 4Varian Medical Systems Acquires Assets of IKOEmed and IKOEtech 3B Acquisition to Add Software for Accelerating Radiotherapy Treatment Planning 12784 1Varian Medical Systems Acquires Assets of IKOEmed and IKOEtech 3B Acquisition to Add Software for Accelerating Radiotherapy Treatment Planning 12784 2Varian Medical Systems Acquires Assets of IKOEmed and IKOEtech 3B Acquisition to Add Software for Accelerating Radiotherapy Treatment Planning 12784 3Humans Werent Always So Special Expert Says 50029 1Humans Werent Always So Special Expert Says 50029 2Obese Poor Shut Out From Weight Loss Surgeries 50027 1Obese Poor Shut Out From Weight Loss Surgeries 50027 2Obese Poor Shut Out From Weight Loss Surgeries 50027 3Obese Poor Shut Out From Weight Loss Surgeries 50027 4Novel handheld device detects anthrax with outstanding accuracy and reliability 8996 1Novel handheld device detects anthrax with outstanding accuracy and reliability 8996 2Novel handheld device detects anthrax with outstanding accuracy and reliability 8996 3
...BUSINESS WIRE)--Jun 4, 2007 - Researchers at,Molec...resentation,of preclinical data on MIP-1072, a rad...ceutical in development for diagnosis and,staging ...he,Society of Nuclear Medicine (SNM) in Washington...es for prostate cancer diagnosis,that Molecular In...
...WIRE)--Jun 4, 2007 - Cytogen Corporation,(NASDAQ: ...demonstrating that QUADRAMET (samarium Sm-153 lexi...ostate cancer patients who are also,receiving the ...s).,Clinical data also support further evaluation ...ostate cancer in a Phase 2 program.,The results we...
Other Medicine Technology:Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 2New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 3New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 5New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 6New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 7
... cost-effective diagnostic test results, rely on t...asy-to-use bench top system fits your point-of-car... it helps you meet your overall laboratory needs -...and improved patient satisfaction., ,The VITRO...
... Market in 1981 with the introduction of the TDx. ...own as FPIA (Fluorescence Polarization Immunoassay.... Therapeutic Drugs, used in the treatment of diff... range requiring close monitoring so the patient r...
Architect i2000SR provides high productivity. Seamless integration optimize performance.
ADVIA Centaur delivers a new level of immunodiagnostic productivity. It provides the flexibility to integrate with any laboratory automation system, now and in the future. Most importantly, it offers
Medicine Products: